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Abstract 
Background:  Angiosarcomas (AS) are rare vascular malignancies. They are subdivided into primary (PAS) and 
secondary angiosarcomas (SAS). The objective was to compare the characteristics of AS subtypes.
Methods: Eighteen PAS and ten SAS patients treated at our institution between 2004 and 2012 were included in this 
study.
Results: Median age of PAS and SAS patients was 52.9 and 64.2 years, respectively (p = 0.1448). The percentage of 
women was 27.8% for PAS, but 80.0% for SAS (p = 0.0163). While PAS occurred throughout the body, the majority 
of SAS arose from the breast (p = 0.0012). All SAS were radiation-induced with a median latency of 7.7 years. The 
majority of patients with PAS and SAS underwent surgery as primary or recurrence treatment (p > 0.95). Local 
recurrence was developed by 27.8% of PAS and 50.0% of SAS (p = 0.4119). 61.1% of PAS metastasized, but only 40.0% 
of SAS (p = 0.4328). Median overall survival for PAS and SAS was 19 and 57 months, respectively (p = 0.2306).
Conclusion: Radical surgery remains the mainstay of both primary and recurrence treatment. SAS show a high local 
recurrence rate, while PAS tend towards developing early metastases. Overall, prognosis is poor for both groups.
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Background
Angiosarcomas (AS) are rare and aggressive malignancies 
representing about 2% of all adult soft tissue sarcomas 
[1]. They arise from endothelial cells of blood vessels or 
lymphatics either sporadically as primary neoplasms or 
secondary to chronic lymphedema or previous irradia-
tion [2]. The latter constitutes an increasing complication 
following breast conserving surgery and radiotherapy 
in patients with breast cancer [3, 4]. Over 200 cases of 
radiation-induced AS of the breast are currently known 
in literature [5]. AS can occur throughout the body: most 
commonly in the head and neck area, followed by breasts 
and extremities. The remainder arise from different local-
izations like the liver, the heart and the bone [6]. The two 
conditions are similar in terms of histopathological fea-
tures and immunohistochemical markers [7]. Secondary 
AS (SAS) differentiate from primary AS (PAS) in their 
pathogenesis by showing high level amplifications of 
MYC as well as FLT4 (VEGFR3) [8, 9]. Evidence-based 
recommendations are missing for the treatment of AS. 
Radical surgical en bloc resection with negative margins 
(R0) is the primary therapy for a potentially curable local-
ized disease [10–12]. When indicated, surgery should 
be completed by adjuvant radiotherapy to prevent local 
recurrence [13, 14]. Inoperable, locally advanced or met-
astatic AS are treated by cytotoxic chemotherapy. Some 
clinical trials displayed that doxorubicin-based regimens 
and paclitaxel are two of the most active agents [15–17]. 
Furthermore, molecularly targeted therapy, in particular 
antiangiogenic therapy, constitutes a new option of treat-
ment. Sorafenib was identified as an active agent against 
AS for instance [18]. Despite all therapeutic efforts, the 
patients’ prognosis is still unfavorable [19, 20]. There is a 
relatively small amount of knowledge about the similari-
ties and differences between the two subtypes of AS. As 
the objective of this retrospective study, the patient and 
tumor characteristics, treatment and outcome of the two 
different types of AS were analyzed.
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Methods
Patients
All adult patients with a confirmed pathohistological 
diagnosis of AS were identified from the Sarcoma Unit 
of the Interdisciplinary Tumor Center of the Univer-
sity Medical Center in Mannheim between 2004 and 
2012. The study population consisted of 28 patients [13 
women (46.4%), 15 men (53.6%)]. Acquisition of clini-
cal data was obtained from the medical records. Patient 
and tumor characteristics including gender, age at diag-
nosis, subtype, tumor site, tumor-related symptoms, as 
well as metastasis at initial diagnosis, treatment, pat-
tern of recurrence, occurrence of metastasis, date of last 
follow-up and survival were recorded and analyzed. In 
case of SAS, both type and age at diagnosis of pre-exist-
ing condition, latent time interval from radiotherapy to 
diagnosis of SAS and dosage of radiation were reviewed. 
This retrospective study was approved by the local ethics 
committee.
Statistical analysis
Progression-free survival (PFS) was defined as the time 
interval from the pathohistological diagnosis of AS until 
the time of first progression (local recurrence or metasta-
sis) or the sarcoma-related death. Patients were censored 
at the last time of follow-up if they did not experience 
any disease progression or death. Overall survival (OS) 
was defined as the period of time from the pathohistolog-
ical diagnosis until the patient’s death. Patients were cen-
sored if they were still alive at the last follow-up. PFS and 
OS were calculated by using the method of Kaplan and 
Meier. Comparison of survival curves were performed by 
log-rank tests. Differences between the two AS subtypes 
were evaluated by t tests or Fisher’s exact tests. StatXact 
9.0 (Cytel Studios 2012, Cambridge, MA, USA) and SAS 
9.2 (SAS Institute Inc. 2013, Cary, NC, USA) were used 
for the statistical analyses. Statistical level of significance 
was set at α = 0.05.
Results
Patients and clinical presentation
Patient and tumor characteristics of PAS and SAS 
are shown in Table  1. From 2004 to 2012, a total of 28 
patients with AS were identified. Of these, 18 patients 
were diagnosed with PAS (64.3%) and ten patients with 
SAS (35.7%). The majority of patients with PAS were rep-
resented by males (n  =  13; 72.2%) while patients with 
SAS were dominated by females (n  =  8; 80%). Fisher’s 
exact test revealed statistical significance in gender distri-
bution between the two groups (p = 0.0163). While PAS 
developed de novo, all patients with SAS had a previ-
ous history of radiotherapy with a median dose of 56 Gy 
(range 50.0–60.4  Gy). The most frequent condition for 
which patients were irradiated was breast cancer (n = 8; 
80%). Further conditions were chronic myeloid leukemia 
(n = 1; 10%) and thyroid gland autonomy (n = 1; 10%). 
The median age at the time of pre-existing diagnosis was 
56.8  years (range 18.5–71.9  years). The median latent 
time interval from radiotherapy to diagnosis of SAS was 
7.7  years (range 4.4–33.5  years). The majority of PAS 
occurred in deep soft tissue or internal organs (n =  12; 
66.7%). Overall, the most common primary tumor sites 
were bone (n  =  4; 22.2%), skin (n  =  4; 22.2%), heart 
(n = 3; 16.7%) and breast (n = 2; 11.1%). In contrast, only 
20% of SAS developed in internal organs [thyroid gland 
(n = 1), liver (n = 1)] and 80% (n = 8) in the breast or 
chest wall. The distribution of tumor localization showed 
a statistically significant difference (p = 0.0012).
Patients with cutaneous AS presented the following 
sites of origin: the scalp, the temple, the upper leg and 
presacral. AS of the bone caused painful restriction of 
mobility and were located in the thoracic vertebras 1–3, 
caput tibiae, os ilium and suprapatellar. All cardiac AS 
were located in the right atrium. AS of the mesentery of 
the small intestine (n = 1) and the adrenal gland (n = 1) 
were accompanied by spontaneous pain. AS of the thy-
roid gland appeared as a rapidly growing knotty swelling 
at the neck. One patient with AS of the deep soft tissue 
presented with a painful mass in the lower leg. AS of 
the breast (n =  2) arose from the parenchyma and pre-
sented with breast enlargement. In a single case, a bilat-
eral localization was found. In contrast, SAS of the breast 
were located in the skin in each case and presented as 
blue-livid discoloration, erythematous plaques, bruise-
like macules, blisters, nodules, indurations or exulcera-
tions. The patient with AS of the liver reported about 
loss of weight, whereas the patient with AS of the thyroid 
gland presented with a painful mass causing swelling 
of the head, dyspnea and difficulties in swallowing. The 
most common metastatic sites at initial diagnosis were 
the lung (n = 2) and the bones (n = 2) in patients with 
PAS and the lung (n = 1) together with the skin (n = 1) in 
patients with SAS.
Primary therapy, recurrences and their treatment
Table  1 describes the initial treatment, the patterns of 
failure and their therapy. Surgical resection was the 
most common primary therapy for both patients with 
PAS (n = 11; 91.7%) and SAS (n = 7; 87.5%) presenting 
with localized disease (p > 0.95). Negative surgical mar-
gins were achieved in 72.7% of the patients with PAS 
(n = 8), while all patients with SAS (n = 7; 100%) were 
curatively resected (p  =  0.2451). Among the ones with 
R0 resection, half of PAS patients (n = 4) received radio-
therapy in adjuvant setting, but none of the SAS patients 
(p  =  0.0769). Local recurrence was observed in 33.3% 
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of PAS patients (n = 4) and 50% of SAS patients (n = 4) 
with nonmetastatic disease at presentation (p = 0.6479). 
Overall, 61.1% of patients with PAS (n = 11) developed 
metastases, but only 40% of patients with SAS (n  =  4) 
(p = 0.4328). In terms of metastatic sites, PAS metasta-
sized most frequently into the lung (n = 4), followed by 
Table 1 Patient, tumor, therapy and recurrence characteristics of PAS and SAS
Characteristic Primary angiosarcomas Secondary angiosarcomas p value
n % n %
Total number of patients 18 64.3 10 35.7
 Male 13 72.2 2 20 0.0163
 Female 5 27.8 8 80
Age at initial diagnosis, median 52.9 years 64.2 years 0.1448
Primary tumor site 0.0012
 Superficial soft tissue or skin 4 22.2 0 0
 Deep soft tissue or internal organs 12 66.7 2 20
 Breast or chest wall 2 11.1 8 80
At initial diagnosis
 Localized disease 12 66.7 8 80 0.6692
 Metastatic disease 6 33.3 2 20
Primary therapy
 Surgical resection >0.95
  Yes 16 88.9 9 90
  No 2 11.1 1 10
 R-status 0.2421
  R0 8 50 8 88.9
  R1 3 18.8 0 0
  R2 1 6.2 0 0
  Unknown 4 25 1 11.1
 Radiotherapy 0.1282
  Yes 5 27.8 0 0
  No 13 72.2 10 100
 Chemotherapy and targeted therapy 0.3642
  Yes 6 33.3 1 10
  No 12 66.7 9 90
 Chemoradiotherapy 0.3571
  Yes 0 0 1 10
  No 18 100 9 90
Recurrence 0.2543
 Yes 8 44.4 7 70
 No 10 55.6 3 30
Local recurrence 5 27.8 5 50 0.4119
Recurrence therapy
 Surgical resection >0.95
  Yes 6 75 5 71.4
  No 2 25 2 28.6
 Radiotherapy >0.95
  Yes 1 12.5 0 0
  No 7 87.5 7 100
 Chemotherapy and targeted therapy 0.3147
  Yes 3 37.5 5 71.4
  No 5 62.5 2 82.6
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the bones (n =  3) and the lymph nodes (n =  3). In the 
two latter sites, SAS did not develop metastases. In fact, 
the skin (n = 2) constituted the most common origin of 
metastases.
Chemotherapy and targeted therapy
The most commonly used chemotherapy regimen or 
targeted therapy agent was the combination of doxoru-
bicin and ifosfamide for patients with PAS (n =  4) and 
single-agent sorafenib for patients with SAS (n  =  5). 
Four patients with PAS underwent chemotherapy treat-
ment with a combination of doxorubicin and ifosfamide: 
two had partial remission (PR) and two had progressive 
disease (PD). Only one patient with SAS receiving these 
two drugs had PR. Patients with PAS (n = 3) treated with 
sorafenib had PD, patients with SAS had stable disease 
(SD) (n = 3) and PD (n = 2). Two PAS patients had SD 
under the combination of doxorubicin and sorafenib, 
whereas SAS patients showed SD (n = 1) and PD (n = 1). 
Both patients with PAS (n = 1) and SAS (n = 1) had com-
plete remission (CR) under treatment with pegylated-
liposomal doxorubicin. In the paclitaxel group, one 
patient with PAS experienced SD, while one patient with 
SAS showed PD.
Survival
The median follow-up was 17.5  months (range 
1–95  months) for PAS patients and 39.5  months (range 
5–90  months) for SAS patients (p  =  0.1235). Eleven 
patients with PAS (61.1%) have died during the study as 
opposed to five patients with SAS (50%). Patients with 
PAS had a median PFS of 9 months (range 1–31 months), 
whereas patients with SAS relapsed after a median dura-
tion of 9.5  months (range 2–23  months) (p  =  0.8139) 
(Figure  1a). Median OS between patients with PAS 
(19  months; range 1–55  months) and SAS (57  months; 
range 6–90 months) did not reach statistical significance 
(p  =  0.2306) (Figure  1b). PAS and SAS 5-year OS rate 
was 6 and 20%, respectively.
Median PFS of PAS and SAS patients who presented 
with localized disease and were initially treated by sur-
gery was 4 months (range 1–31 months) and 13 months 
(range 2–23 months), respectively (p = 0.5943). If nega-
tive surgical margins were achieved, median PFS was 
10  months (range 2–31  months) and 13  months (range 
2–23  months) for PAS and SAS patients, respectively 
(p  =  0.6188). PAS and SAS patients presenting with 
nonmetastatic disease had a median survival from ini-
tial diagnosis to appearance of local recurrence of 
19.5 months (range 2–31 months) and 10 months (range 
2–23 months), respectively (p = 0.3045), whereas median 
PFS was 4.5 months (range 1–31 months) and 12 months 
(range 2–23 months), respectively (p = 0.5570).
Discussion
Primary and secondary AS are rare and aggressive neo-
plasms. The current analysis of 28 patients compared 
characteristics of these two subtypes demonstrating 
both similarities and differences. In this series, overrep-
resentation of SAS, female preponderance and the high 
percentage of breast SAS could be seen as a consequence 
of an increasing use of breast conserving therapy with 
postoperative radiotherapy in patients with breast car-
cinoma. That therapeutic procedure is associated with 
an about 3,200 times increased relative risk to develop 
SAS [21]. The median latency period from irradiation 
to diagnosis of SAS was 7.7  years. This fact was similar 
to findings in previous studies [7, 19]. Besides, the aver-
age latency tends to be shorter for breast SAS than for 
non-breast SAS (6.7 vs. 20.9  years; p  =  0.148) [7]. In 
Figure 1 Survival of patients with PAS and SAS. Kaplan–Meier curves for a progression-free survival (p = 0.8139) and b overall survival (p = 0.2306) 
for patients with PAS (solid line) and SAS (dashed line).
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one case, breast SAS occurred after a latent time inter-
val of 33.5 years being unusual for radiation-induced AS. 
Such a long period of time is rather reported for other 
radiation-induced sarcomas [22]. Postirradiation breast 
sarcomas (excluding AS) are generally diagnosed after a 
mean latency period of 14.3  years. In particular, radia-
tion-induced breast malignant fibrous histiocytomas and 
fibroblastic sarcomas develop after a longer latency as 
opposed to postirradiation breast AS (p < 0.05) [23].
In this series, the percentage of surgery as initial ther-
apy was higher than in previous reports (about 90 vs. 
68–75%) [11, 19]. Negative microscopic margins were 
obtained in 88.9% of SAS patients, but only in half of PAS 
patients (p =  0.2421). This might be related to surgical 
methods depending on primary sites. In case of breast 
AS, R0 resection could be easily achieved through mas-
tectomy (74% [24]). In opposition to that, resection of 
heart or cutaneous AS causes difficulties (0 and 21.3%, 
respectively [25, 26]) due to a potential tumor spread 
around vital structures. Furthermore, median PFS was 
increased by surgical resection in PAS patients presented 
with localized tumors when negative microscopic mar-
gins were achieved (4 to 10 months). SAS patients were 
not evaluated because all patients treated by surgery 
had R0 resection. Jallali et  al. [27] found out that cura-
tively resected patients with radiation-induced AS after 
breast conserving therapy had improved median survival 
compared to patients with incomplete excision (42 vs. 
6 months). In general, surgical margin status has a major 
impact on patients’ outcome since wide surgical resec-
tion with microscopically negative margins is accompa-
nied by significantly prolonged OS and disease-specific 
survival (DSS), respectively [12, 20].
Radiotherapy constitutes another treatment option, 
preferably in the adjuvant setting. Mark et  al. [13] 
observed statistically significant difference in 5-year OS 
between patients treated with and without additional 
radiotherapy, respectively (54 vs. 19%; p = 0.03). In our 
series, 27.8% of PAS patients received radiotherapy, but 
none of SAS patients (p = 0.1282). The latter have already 
received the maximum dose of radiotherapy in terms of 
predisposing disease. Nevertheless, in the Riad series, the 
risk of developing local recurrence was lower in patients 
with radiation-induced sarcomas, if they were reirradi-
ated after surgical treatment (p  =  0.043) [28]. Overall, 
Buehler et  al. [19] analyzed AS patients with localized 
disease undergoing surgical resection and irradiation. 
They observed a decreased local recurrence rate (31 vs. 
41%) and prolonged time to local recurrence (median 10 
vs. 4 months).
In general, patients with inoperable, advanced or met-
astatic disease are treated by cytotoxic chemotherapy. 
However, the use is often hampered by the advanced age 
of patients, their co-morbidities and toxicities. The best 
outcome in our series was observed with pegylated-lipo-
somal doxorubicin. Skubitz and colleagues [29] reported 
on six patients receiving this drug but none of them had 
CR. Three patients had PR, two had SD and one had PD. 
A study by Italiano evaluated efficacy of doxorubicin and 
weekly paclitaxel in 117 metastatic AS patients. They 
found out that response rate of both drugs was higher in 
patients with SAS as opposed to patients with PAS [16].
An alternative treatment option to conventional 
chemotherapy represents molecular targeted therapy 
in the form of angiogenesis inhibition, e.g. by sorafenib 
or bevacizumab. Maki et al. [18] assessed the efficacy of 
sorafenib in 145 patients with metastatic or recurrent sar-
comas. These included 25 PAS patients (2 PR; response 
rate 8%) and 9 SAS patients (1 CR, 2 PR; response rate 
33.3%). Sorafenib seems to be more active in patients 
with SAS as opposed to patients with PAS. In a phase II 
trial from the French Sarcoma Group (GSF/GETO) with 
41 advanced AS patients, sorafenib showed a response 
rate of 23% in chemotherapeutical pretreated population 
whereas chemotherapy-naive patients had no response 
[30]. In contrast, no response could be observed in our 
series, irrespective if pretreated or not.
Our analysis is limited for various reasons. Firstly, the 
retrospective nature reduced the quality of data since 
there is no predefined therapeutic algorithm. In fact, AS 
represent rare and especially heterogeneous neoplasms 
why this single-center study is primarily descriptive. 
Furthermore, our small total number of patients was 
divided into more homogeneous subgroups to counter-
act limitations of outcome analysis. However, the impact 
of different treatment options, in particular the role of 
chemotherapy, targeted therapy and their combination, 
cannot be addressed adequately in this series and there-
fore has to be taken into account when interpreting the 
results. Accordingly, further evaluations with larger study 
populations are urgently needed.
Median survival from diagnosis to local recur-
rence tended to be longer in PAS patients compared to 
SAS patients with initially localized disease (19.5 vs. 
10 months; p = 0.3045). According to Abraham et al. [10] 
the difference is clearly significant, resulting in a higher 
risk of local recurrence of SAS patients as opposed to PAS 
patients (p = 0.0001). While median PFS of all PAS and 
SAS patients showed similar results (9 vs. 9.5  months; 
p =  0.8139), it tends to be shorter in PAS patients pre-
senting with nonmetastatic disease than in SAS patients 
(4.5 vs. 12 months; p = 0.5570). This observation might 
be caused by the more frequent occurrence of metasta-
ses in PAS patients during the course of the disease. OS 
analyses in different subgroups is hampered by both lack 
of endpoints and the small number of patients. However, 
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AS arising within irradiated tissue in patients with non-
metastatic disease tended to have a shorter OS compared 
to patients with AS in other sites including lymphedem-
atous fields in the Lindet series (26.5 vs. 45.9  months; 
p = 0.255). It must be taken into consideration that 22.4 
and 62.6% of the entire cohort consist of patients with 
AS in pre-existing lymphedema and previously irradi-
ated fields, respectively [31]. In particular, the outcome of 
PAS patients is significantly associated with longer DSS 
in comparison to SAS patients (p =  0.007) [10]. Differ-
ent OS was observed between all patients with PAS and 
SAS in our series (19 vs. 57 months; p = 0.2306). Possi-
ble causes of the outcome are the diverse tumor biology, 
the primary site and the related therapy options. Hung 
et  al. [7] also found no significant difference between 
PAS and SAS patients. Instead, shorter OS were observed 
in patients with breast SAS as opposed to patients with 
non-breast SAS. Moreover, Vorburger et al. [32] observed 
no statistically difference in terms of OS between patients 
with PAS and SAS of the breast. Overall, the prognosis 
remains poor for both PAS and SAS patients, but there 
seems to be a better perspective for the latter (5-year OS 
rate 6 and 20%, respectively). Furthermore, median OS 
of advanced soft-tissue sarcomas was 11.7 months in the 
Blay series [33]. In view of this fact, SAS belong to the 
circle of sarcoma entities with the best outcome.
Conclusion
In conclusion, we have demonstrated that primary and 
secondary AS constitute not only a rare and thoroughly 
aggressive, but also a heterogeneous disease. PAS occur 
at different localizations in the body while the majority of 
SAS arise from the breast of female patients. SAS show a 
high local recurrence rate, while PAS tend towards devel-
oping metastases. Radical surgical resection remains the 
mainstay of both primary and recurrence treatment. In 
future, multicenter prospective randomized trials should 
investigate new therapeutic strategies like the combina-
tion of molecular targeted therapy and cytotoxic chemo-
therapy. The prognosis is poor for both AS subtypes, but 
there seems to be a better outcome for SAS. While PFS 
shows similar results among the two groups, it tends to 
be shorter in PAS patients presenting with localized dis-
ease at initial diagnosis compared to SAS patients. How-
ever, subdivision of patients into more homogeneous 
subgroups is limited by our small number of patients. 
Also the study’s retrospective nature and the rarity of 
the disease have an impact on the results which has to be 
considered. Hence, the relationship of primary and sec-
ondary AS has to be investigated, particularly in terms 
of molecular biology and clinicopathological features, in 
order to improve the specific treatment options and sub-
sequently the survival.
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